Meeting
2023 ASCO Annual Meeting
Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.
Authors
Po-Han Lin
National Taiwan University Hospital, Taipei City, Taiwan
Po-Han Lin , Li-Wei Tsai , Chiao Lo , Sung-Hsin Kuo , Chiun-Sheng Huang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 558)
DOI
10.1200/JCO.2023.41.16_suppl.558
Abstract #
558
Poster Bd #
388
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.
First Author: Yvonne Brandberg
Poster
2019 ASCO Annual Meeting
Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer.
First Author: Yvonne Brandberg
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
Poster
2023 ASCO Annual Meeting
A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD).
First Author: Mitchell Elliott